Whole exome sequencing revealed a novel dystrophin-related protein-2 (DRP2) deletion in an Iranian family with symptoms of polyneuropathy

Document Type: Short Communication

Authors

1 Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

3 Noor Genetics Lab. Ahvaz, Iran

4 Iranian Social Security Organization, Labafinejad Hospital, Tehran, Iran

5 Aboozar Children’s Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Objective(s): Charcot-Marie Tooth disease (CMT) is one of the main inherited causes of motor and sensory neuropathies with variable expressivity and age-of onset. Although more than 70 genes have been identified for CMT, more studies are needed to discover other genes involved in CMT. Introduction of whole exome sequencing (WES) to capture all the exons may help to find these genes.
Materials and Methods: Here, we tried to find the genetic cause of the neuropathy in two Iranian brothers using WES. Blood sample was collected from probands and their family members to extract the genomic DNA. The extracted DNA from one of the affected case was subjected for WES. The variant calls were filtered  to reveal the pathogenic variant. Presence of the candidate mutation was confirmed using Sanger sequencing. The pathogenic potential of the variant was examined using in silico software. Using ClustalW multiple alignment, the presence of variant in conserved domain of protein was investigated. The parent and another affected boy were also checked for presence of the variant using PCR-sequencing.
Results: The obtained data presented a novel TTC del mutation in CDS 738 of dystrophin related protein 2 (DRP2) gene, which was validated by sequencing. The variant was located in a conserved domain of DRP2 protein and predicted as pathogenic. Two affected boys were hemizygous for the mutation and received the mutation from mother.
Conclusion: Here, we provided the evidence for the contribution of DRP2 in CMT. Also, the symptoms shed light on molecular aspect of this genetically heterogeneous disease.

Keywords

Main Subjects


1. Azzedine H, Senderek J, Rivolta C, Chrast R. Molecular genetics of charcot-marie-tooth disease: from genes to genomes. Mol Syndromol 2012; 3:204-214.
2. Hoyle JC, Isfort MC, Roggenbuck J, Arnold WD. The genetics of Charcot–Marie–Tooth disease: current trends and future implications for diagnosis and management. Appl Clin Genet 2015; 8:235-243.
3. Szigeti K, Lupski JR. Charcot–Marie–Tooth disease. Eur J Hum Genet  2009; 17:703-710.
4. Verma A. Next-generation sequencing and genetic diagnosis of Charcot-Marie-Tooth disease. Ann Indian Acad Neurol 2014; 17:383-386.
5. Hoyle JC, Isfort MC, Roggenbuck J, Arnold WD. The genetics of Charcot–Marie–Tooth disease: current trends and future implications for diagnosis and management. Appl Clin Genet 2015; 8:235-43.
6. van Paassen BW, van der Kooi AJ, van Spaendonck-Zwarts KY, Verhamme C, Baas F, de Visser M. PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies. Orphanet J Rare Dis  2014; 19: 9-38.
7. Brennan KM, Bai Y, Pisciotta C, Wang S, Feely SM, Hoegger M, et al. Absence of Dystrophin Related Protein-2 disrupts Cajal bands in a patient with Charcot-Marie-Tooth disease. Neuromuscul Disord 2015; 25:786-793.
8. Çağlayan AO. Clinical utility of next-generation sequencing in neurodevelopmental disorders: non-syndromic intellectual disability as a model.  FNG & Bilim Tıp Dergisi 2015;1:52-57.
9. Warr A, Robert C, Hume D, Archibald A, Deeb N, Watson M. Exome sequencing: current and future perspectives. G3 (Bethesda) 2015; 5:1543-1550.
10. Fromer M, Moran JL, Chambert K, Banks E, Bergen SE, Ruderfer DM, et al. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet 2012; 91:597-607.
11. Jani-Acsadi A, Krajewski K, Shy ME, editors. Charcot-Marie-Tooth neuropathies: diagnosis and management. Semin Neurol.; 2008: 28:185-194.
12. Fabrizi GM, Cavallaro T, Angiari C, Cabrini I, Taioli F, Malerba G, et al. Charcot–Marie–Tooth disease type 2E, a disorder of the cytoskeleton. Brain 2006; 130:394-403.
13. Rezende RL, Bonjardim LR, Neves EL, Santos LC, Nunes PS, Garcez CA, Souza CC, Araújo AA. Oral health, temporomandibular disorder, and masticatory performance in patients with charcot-marie-tooth type 2. Scientific World Journal 2013; 2013:425651.
14. Karol LA, Elerson E. Scoliosis in patients with Charcot-Marie-Tooth disease. JBJS 2007; 89:1504-1510.
15. Bamford NS, White KK, Robinett SA, Otto RK, Gospe Jr SM. Neuromuscular hip dysplasia in Charcot–Marie–Tooth disease type 1A. DMCN 009; 51:408-411.
16. Roberts RG, Freeman TC, Kendall E, Vetrie DL, Dixon AK, Shaw-Smith C, et al. Characterization of DRP2, a novel human dystrophin homologue. Nat Genet 1996; 13:223-226.
17. Roberts RG, Sheng M. Association of Dystrophin-Related Protein 2 (DRP2) with Postsynaptic Densities in Rat Brain. Mol Cell Neurosci 2000; 16:674-685.
18. Gee SH, Madhavan R, Levinson SR, Caldwell JH, Sealock R, Froehner SC. Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins. J Neurosci 1998; 18:128-137.
19. Šedivá A, Smith CE, Asplund AC, Hadač J, Janda A, Zeman J, et al. Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. J Clin Immunol 2007; 27:640-646.
20. Toma C, Torrico B, Hervás A, Valdés-Mas R, Tristán-Noguero A, Padillo V, et al. Exome sequencing in multiplex autism families suggests a major role for heterozygous truncating mutations. Mol Psychiatry 2014; 19:784-790.